FDA Brief

Warning letters Devices

FDA warning letter to

Owens & Minor, Inc. dba American Contract Systems, Inc.

High riskIssued Nov 1, 2024Posted Nov 12, 2024Center for Devices and Radiological Health

FDA warned Owens & Minor unit American Contract Systems over device quality-system violations for sterile kits, including failed sterilization bags and incomplete design verification.

What happened

During an August 5 through 14, 2024 inspection of the Tiffin, OH facility, FDA found the firm makes sterile convenience kits and was not in conformity with the Quality System regulation for devices. FDA found that the firm accepted four sterilization bag lots from January through July 2024 that failed thickness requirements and used them in ethylene oxide sterilization, and it lacked complete design verification/validation and design history files for 25 FDA product codes.

What FDA found

  1. FDA says the firm accepted four sterilization bag lots that failed its thickness requirements and used them in ethylene oxide sterilization.

    21 CFR 820.80(b)
  2. FDA says the firm did not complete design verification and validation for 25 FDA product codes, including two components in the C-Section Pack.

    21 CFR 820.30(a); 21 CFR 820.30(g)
  3. FDA says the firm did not have complete design history files for 25 FDA product codes.

    21 CFR 820.30(j)

What FDA wants

FDA asks the firm to respond in writing within 15 business days with the steps taken, systemic corrective actions, and a timetable, and to describe how it will complete the component review and ensure that only devices with complete design history files are distributed.

Who should pay attention

  • hospitals and surgical teams using sterile convenience kits
  • distributors and brands selling ACS sterile kits
  • contract manufacturers of sterile procedure packs

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Baxter International Inc.

    Baxter's Round Lake injectable drug plant violated CGMP (manufacturing quality rules), with cephalosporin cross-contamination and sterile processing failures.

    High risk
  2. Hanlim Pharm Co., Ltd.

    FDA warned Hanlim Pharm over serious sterile manufacturing violations, including poor aseptic practices and airflow problems, at its South Korea plant.

    High risk
  3. Empower Clinic Services, LLC dba Empower Pharmacy

    FDA warned Empower Pharmacy over unapproved compounded semaglutide/tirzepatide copies and sterile manufacturing deficiencies that put patients at risk.

    High risk
  4. Excelvision - Fareva

    FDA warned Excelvision-Fareva after a 2026 inspection found inadequate contamination investigations and aseptic failures for sterile drugs.

    High risk